- Design
- Phase 3, randomised, open-label, sponsor-blinded, three-arm trial
- Population
- 760 adults with embolisation-eligible HCC, Child-Pugh A, ECOG 0–1
- Primary outcome
- Progression-free survival, STRIDE + lenvatinib + TACE vs TACE
- Effect
- 13.0 vs 9.8 months, HR 0.70 (0.57 to 0.86); OS HR 0.84 (0.65 to 1.09)
EMERALD-3 was a global phase 3, open-label trial in 760 patients with hepatocellular carcinoma (HCC) not suitable for curative treatment but eligible for transarterial chemoembolisation (TACE), with Child-Pugh A liver function. Patients received STRIDE (single-dose tremelimumab with regular durvalumab) plus lenvatinib plus TACE, STRIDE plus TACE, or TACE alone. 72% were Asian.
Median progression-free survival was 13.0 months with STRIDE, lenvatinib and TACE against 9.8 with TACE (HR 0.70). STRIDE plus TACE also improved it (12.9 against 8.1; HR 0.71). At the second cut-off, overall survival was 39.5 against 34.7 months (HR 0.84, 0.65 to 1.09), not significant. Serious adverse events occurred in 64% with the triplet, 51% with STRIDE plus TACE and 23% with TACE; treatment-related deaths were 2%, 0% and 1%.
Adding systemic therapy to TACE now has phase 3 support for delaying progression, following earlier trials with other combinations. Whether it extends life is not yet shown, and the triplet roughly triples serious adverse events. STRIDE plus TACE without lenvatinib gave a similar progression-free benefit with no treatment-related deaths, a comparison worth noting while overall survival matures.
- Discuss combination systemic therapy with TACE for Child-Pugh A intermediate-stage HCC in a tumour board
- Weigh progression-free benefit against a much higher serious adverse event rate
- Screen for autoimmune disease, varices and cardiac risk before immunotherapy
- Monitor blood pressure closely on lenvatinib
- Consider cost and access, which in India will limit these regimens
Why it matters
It adds to the case for moving immunotherapy earlier in HCC, without yet showing a survival gain.
Don't overread it
Overall survival was not significantly improved at this analysis, and progression-free survival is a surrogate in HCC.
The statistics, in plain English
A progression-free survival hazard ratio of 0.70 means a 30% lower rate of progression or death, a clear effect. The overall survival HR of 0.84 with an interval from 0.65 to 1.09 is compatible with a 35% reduction or a 9% increase, so no conclusion is possible yet. Open-label trials can inflate progression-free survival if imaging timing or interpretation differs between arms.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free